Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,871 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrate Control Clear all
Recruiting Phase 2Phase 3 Interventional

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

NCT06191965
View directory record Official record
Conditions
Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
Interventions
MitoQ, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 29, 2026, 11:53 PM EDT
Recruiting Phase 4 Interventional

Placement of Antibiotic Powder in Wounds During the Emergency Room

NCT03765567
View directory record Official record
Conditions
Open Fracture
Interventions
Vancomycin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 2 Interventional

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02057172
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
HM11260C, liraglutide, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 74 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
CA, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 29, 2026, 11:53 PM EDT
Recruiting Phase 4 Interventional

Lactated Ringer's and Dextrose 5% vs Only Lactated Ringer's in Labor

NCT07124130
View directory record Official record
Conditions
Induced Labor
Interventions
5% Dextrose (D5) in Normal Saline (NS), Lactate Ringer
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Not applicable Interventional

A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)

NCT03362151
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Regular pasta, High protein pasta, White rice
Other
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Not applicable Interventional

Patient Preparedness for Pelvic Organ Prolapse Surgery

NCT03836365
View directory record Official record
Conditions
Pelvic Organ Prolapse, Patient Preparedness
Interventions
Preoperative counseling office visit, Preoperative counseling phone call
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 99 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 29, 2026, 11:53 PM EDT
Terminated Not applicable Interventional

Effect of Meal Composition and Timing Modification on Glucose Metabolism, Body Temperature and Sleep

NCT05413928
View directory record Official record
Conditions
PreDiabetes, Type 2 Diabetes, Healthy
Interventions
Time Restrictive Eating- late, Time Restrictive Eating- early, Time Restrictive Eating- early with early caloric intake, Macronutrient-controlled meals
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 29, 2026, 11:53 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease

NCT02066571
View directory record Official record
Conditions
Parkinson's Disease, Freezing of Gait, Cognitive Ability, General
Interventions
Droxidopa, sugar pill
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
30 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 29, 2026, 11:53 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

NCT07224334
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

NCT01756404
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Not applicable Interventional Results available

Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia

NCT01793935
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sensoril®, Placebo
Drug
Lead sponsor
K.N. Roy Chengappa
Other
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

NCT02883049
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
Interventions
Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
5,949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT02680574
View directory record Official record
Conditions
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
219
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 158 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 29, 2026, 11:53 PM EDT
Withdrawn Phase 2 Interventional

NRX-1074 in Early Course Schizophrenia

NCT02603458
View directory record Official record
Conditions
Schizophrenia
Interventions
NRX-1074, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Message Modality of Culturally Appropriate Nutrition Communication for Mexican American Women

NCT04710108
View directory record Official record
Conditions
Sugar Sweetened Beverage Consumption, Nutrition, Lifestyle-related Condition, Lifestyle Risk Reduction
Interventions
Health Communication
Other
Lead sponsor
University of California, Merced
Other
Eligibility
18 Years to 29 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Merced, California
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

NCT03347708
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
IDCT, Saline Solution, Sodium Hyaluronate
Biological · Drug
Lead sponsor
DiscGenics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 29, 2026, 11:53 PM EDT
Not listed Phase 2 Interventional

Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)

NCT01221792
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Carvedilol, Placebo
Drug
Lead sponsor
Columbia Northwest Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
San Diego, California • Lake Charles, Louisiana • Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 4 Interventional Results available

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

NCT01524705
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin Glargine, Metformin, Prandial insulin, Exenatide
Drug
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study

NCT04543877
View directory record Official record
Conditions
Inflammation, Vaccine, Intestinal Permeability, Typhoid Fever
Interventions
Inulin, Maltodextrin, Ty21a Typhoid Fever Vaccine
Dietary Supplement · Biological
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 29, 2026, 11:53 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fiber's Utilization for Energy and Life

NCT05934357
View directory record Official record
Conditions
Diet Habit
Interventions
Fiber, Control
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
22 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 29, 2026, 11:53 PM EDT
Terminated Phase 1 Interventional

The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures

NCT04198129
View directory record Official record
Conditions
Jaw Fractures, Infection
Interventions
Antibiotic treatment (Unasyn or Cleocin), Antibiotic treatment (Augmentin or Cleocin), Control Group
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 29, 2026, 11:53 PM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (Stable Dose) Weight Loss Study

NCT01272765
View directory record Official record
Conditions
Obesity
Interventions
Placebo, IHBG-10
Other · Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 29, 2026, 11:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Obesity Observational Prospective Trial

NCT03139877
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
10 Years to 18 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

NCT00046501
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
9 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 29, 2026, 11:53 PM EDT